Review

Molecular pharmacology in a simple model system: Implicating MAP kinase and phosphoinositide signalling in bipolar disorder

Marthe H.R. Ludtmann, Katrina Boeckeler, Robin S.B. Williams

Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London, Egham TW20 0EX, UK

ABSTRACT

Understanding the mechanisms of drug action has been the primary focus for pharmacological researchers, traditionally using rodent models. However, non-sentient model systems are now increasingly used as an alternative approach to better understand drug action or targets. One of these model systems, the social amoeba Dictyostelium, enables the rapid ablation or over-expression of genes, and the subsequent use of isogenic cell culture for the analysis of cell signalling pathways in pharmacological research. The model also supports an increasingly important ethical view of research, involving the reduction, replacement and refinement of animals in biomedical research. This review outlines the use of Dictyostelium in understanding the pharmacological action of two commonly used bipolar disorder treatments (valproic acid and lithium). Both of these compounds regulate mitogen activated protein (MAP) kinase and inositol phospholipid-based signalling by unknown means. Analysis of the molecular pathways targeted by these drugs in Dictyostelium and translation of discoveries to animal systems has helped to further understand the molecular mechanisms of these bipolar disorder treatments.

© 2010 Elsevier Ltd.

Contents

1. Introduction .......................................................................................................................................... 105
2. Bipolar disorder background .................................................................................................................. 106
3. Dictyostelium as a model for pharmacology ............................................................................................ 106
4. A summary of valproic acid’s molecular mechanisms of action ................................................................. 107
5. A summary of lithium’s molecular mechanisms of action ......................................................................... 107
6. MAP Kinase and bipolar disorder ........................................................................................................... 108
7. Inositol and phosphoinositol attenuation and bipolar disorder ................................................................. 108
8. Conclusion/summary ........................................................................................................................... 110
Acknowledgements ................................................................................................................................... 111
References ............................................................................................................................................... 111

1. Introduction

Bipolar disorder, a neurological condition that causes cyclic variation in mood, gives rise to a devastating effect on quality of life and significantly increases the chance of suicide [1]. To improve diagnosis and treatment of bipolar disorder, ongoing research has focused on identifying the molecular basis of the condition. Research models used for this purpose have traditionally been rodents. However, the increasing use of other simple model systems such as the social amoeba, Dictyostelium discoideum, provides distinct advantages. The following review will introduce bipolar disorder and Dictyostelium as a biomedical model. The review will then focus on...
two of the most widely used bipolar disorder treatments – valproic acid (VPA) and lithium – by firstly outlining current knowledge of cell signalling pathways regulated by each treatment, and then illustrating the use of Dictyostelium (and subsequent translation to mammalian systems) to enhance our understanding of putative bipolar disorder-dependent cell signalling changes in both pathways.

2. Bipolar disorder background

Bipolar disorder (also known as manic depression) is a neurological condition giving rise to cyclic and extreme changes in mood. The two most widely occurring types of bipolar disorder are characterised by slightly different re-occurring states: type 1 describes recurrent mood swings from depression to mania, whilst type 2 describes recurrent mood swings from depression to euthymic (stabilised mood) behaviour or mild forms of mania [2–4]. Bipolar disorder is amongst the most common serious neurological disorders, with estimates of its worldwide occurrence of up to 4% [4–6]. An equal number of men and women develop this illness, and its frequency is highest in people from a low economic bracket or in offspring of those in higher socio-economic indices [7]. In the UK the financial burden on the health system amounts to €4.6 billion annually [8] and although it does not in itself cause physical bodily damage, it gives rise to emotionally damaging behaviour and bears a 15% risk of suicide when left untreated [9]. A recent US study suggests that bipolar disorder occurrence doubled in adults and increased by 40-fold for those under 20 years old from 1994 to 2003 [10]. Many studies suggest an heritable risk, since monozygotic twins indicate a 60% co-inheritance which decreases to 7% for first-degree relatives [11].

Current treatments for bipolar disorder include lithium, anticonvulsant drugs (carbamazepine, Tegretol), valproic acid (Depakote), gabapentin (Neurontin) and lamotrigine (Lamictal), antidepressants such as buproprion (Wellbutrin) or sertraline (Zoloft), neuroleptics (e.g. haloperidol) and benzodiazepines (e.g. lorazepam). These treatments require continuous long-term use and are thus non-curative. A decision on which treatment to use is normally based on individual symptoms. Poor response rates to drug treatment (only marginally better than placebo) occur in approximately 35–50% of patients, with significant side effects that often lead to non-adherence [12].

Research into bipolar disorder remains a hugely complex undertaking. This is primarily since there are no well accepted models for the condition [13], patients cannot be taken off treatment since this may give rise to damaging mood changes, and since the molecular mechanism of bipolar disorder drugs have not been discovered. For these reasons current treatments have been found as a secondary effect whilst treating other conditions (e.g. epilepsy). However, three broad approaches continue to be used in bipolar disorder research: genetics, physiology and pharmacology.

- **Genetics**: Identifying the genetic basis of bipolar disorder is likely to provide the ultimate origin of the condition and is thus a fundamentally important approach. There is clear evidence that the occurrence of bipolar disorder has a strong genetic component [14] and a range of specific loci have been associated with the disorder [15,16]. However, as a consequence of the large number of loci involved, this approach is highly complex.

- **Biochemistry**: Understanding physical changes in individuals with bipolar disorder may provide an avenue to identify the molecular basis of the condition. For example, recent studies have shown bipolar disorder-dependent changes in brain volume [17,18], brain imaging studies [19], in gene expression [20], enzymatic activity [21] and in the regulation of cellular components such as fatty acids [22,23].

- **Pharmacology**: The identification and characterisation of changes in cell signalling caused by bipolar disorder treatments may both identify the molecular mechanism causing bipolar disorder, and enable the development of more efficacious treatments or treatments with reduced side effects. The vast array of genetic risk factors associated with bipolar disorder occurrence is expected to give rise to changes in only a limited number of signalling pathways that are then controlled by a small number of current bipolar disorder treatments. Thus understanding bipolar disorder-associated signalling pathways may help the treatment of patients with a wide array of causative factors. However, this approach is also complex since bipolar disorder treatments have numerous effects and/or targets, and the primary sites of action are often unknown. The majority of research into the molecular basis of bipolar disorder treatments has centred on valproic acid (VPA) and lithium.

3. Dictyostelium as a model for pharmacology

The use of invertebrate, non-sentient model organisms can facilitate our understanding of the mechanism of drug action on cellular level whilst reducing the use of animals in research. Dictyostelium discoideum is one of these models listed as one of ten non-mammalian biomedical models recognised by the US National Institutes of Health (NIH). Dictyostelium is more complex than other models listed such as Saccharomyces cerevisiae (baker’s yeast), Schizosaccharomyces pombe (fission yeast) or Neurospora crassa (filamentous fungus) since Dictyostelium cells undergo chemotactic and random movement. It also has rudimentary development mechanisms and related signalling pathways. On the other hand, Dictyostelium is simpler than other models listed such as Caenorhabditis elegans (round worm) and Drosophila melanogaster (fruit fly), Danio rerio (zebrafish), and Xenopus tropicalis (frog) since it lacks the much more complex developmental processes involved in the formation of these animals and lacks their basic neurological networks. Dictyostelium has evolved a strong niche for studies into cell movement and development [24–26], for understanding the cellular role of a range of proteins [27], for evolutionary biology [28] and for a growing range of biomedical research areas outlined in this edition.

Dictyostelium can be cultured by either growth in nutrient rich media (ingesting media via macropinocytosis) or in association with bacteria as a food source (ingesting bacterial cells via endocytosis), and will continue to divide by binary fission until food or nutrients are depleted. Thus, in the presence of sufficient nutrients, large quantities of isogenic cells can be cultured and used for biochemical or cell signalling studies (Fig. 1).

Dictyostelium as a model for pharmacology

Dictyostelium can be cultured by either growth in nutrient rich media (ingesting media via macropinocytosis) or in association with bacteria as a food source (ingesting bacterial cells via endocytosis), and will continue to divide by binary fission until food or nutrients are depleted. Thus, in the presence of sufficient nutrients, large quantities of isogenic cells can be cultured and used for biochemical or cell signalling studies (Fig. 1). Dictyostelium also has an unusual part of its life cycle, whereby starvation initiates a development cycle and a range of genes are transcribed enabling chemically-directed cell movement (chemotaxis) and aggregation of ~100 000 cells to a single point, followed by a primitive developmental process leading to the formation of distinct cell types (spore and stalk cells) in a mature fruiting body (Fig. 1). This development process takes around 24h.

The haploid genome of this Dictyostelium has been fully sequenced [29] and contains 34 Mb of DNA which is 84-fold smaller than the human genome, but encodes 12,500 genes. Many of these genes now contain considerable annotation by the online research resources [Dictybase.org [30]]. Unusual aspects of the Dictyostelium genome include a high AT/GC ratio (86:14) and an average open reading frame of 1756 bp with 1.9 introns per gene. Dictyostelium provides a simple model system that is well-characterised at a genetic level.

The use of Dictyostelium as a pharmacological and pharmacogenetic molecular model for VPA and lithium was initially based upon...
the observation that both drugs block development, thus enabling a range of studies to understand their mechanism(s) of action (Fig. 1):

- REMI mutagenesis (Restriction Enzyme Mediated Insertional mutagenesis [31–33]) provides an approach to create a library of insertion mutants, whereby a selectable marker is randomly integrated throughout the genome. The resulting pool of mutants can then be screened for resistance to VPA or lithium. Mutants with resistance to the block in development will identify the loci that control VPA or lithium action [34].
- Specific genes can be deleted within the haploid genome, and clonal cell lines can be isolated and used for biochemical or developmental resistance studies. The recent adaption of Cre-Lox based excision technology in Dictyostelium now enables the sequential repetition of this process, and thus the targeted ablation of multiple genes in a single cell line [35]. For example, Kay and co-workers recently ablated six genes in a single cell line [36].

4. A summary of valproic acid’s molecular mechanisms of action

Valproic acid is a simple branched, short chain fatty acid (2-propylpentanoic acid), that was accidentally discovered to function in seizure control in the early 1960s [38]. Since then its role has expanded to include its application as a mainstay treatment for bipolar disorder [39,40] and as a widely used prophylactic treatment for migraine [41]. More recently, it has also been proposed as a new treatment for a variety of conditions including ischemia [42], cancer [43], Alzheimer’s disease [44], latent HIV [45], in terminal blood loss [46] and traumatic brain injury [47]. In addition to the beneficial effects of VPA, it also has a number of significant side effects. These include teratogenicity [48], whereby unborn children have a significantly increased chance of birth defects if the drug is taken by the mother during the first trimester of pregnancy [49], hepatotoxicity [50] and a range of common adverse side effects including weight gain, tremor, alopecia [51].

Not surprisingly, this gamut of therapeutic roles for VPA has been associated with a variety of cellular mechanisms. These range from increasing gamma aminobutaric (GABA) levels [41], reducing de novo inositol synthesis [52,53] and inositol trisphosphate depletion (InsP3) [54,59,99], to reducing ion channel activity [55], in regulation of fatty acid signalling and turnover [56] and in the activation of the mitogen activated protein (MAP) kinase pathway [57]. A role for VPA in GSK3 signalling has also been proposed, initially through direct inhibition [58], although this could not be reproduced by other groups [59,60]. Subsequent experiments showed contrasting results for an indirect effect of VPA on GSK3, primarily by elevated soluble β-catenin levels following treatment [61]. Histone deacetylase inhibition [60] has also been shown to provide a mechanism of action for VPA—an effect linked to teratogenicity [62].

5. A summary of lithium’s molecular mechanisms of action

The mechanism of action for lithium has been of considerable interest since its re-discovery as a bipolar disorder treatment by Cade [63]. Lithium is the most commonly used treatment for bipolar disorder, and it is also effective in reducing pathological processes in a variety of Alzheimer’s disease models [64]. Side effects include mild tremor, nausea, diarrhea and its therapeutic window is narrow thus requiring regular monitoring of lithium blood concentration [65]. Furthermore, lithium has been proposed to be a teratogen since administration during pregnancy also increases the risk of congenital heart defects [66].

Despite the simple nature of this molecule (the third element on the periodic table), it still remains unclear how lithium functions in its therapeutic action. However, it has been widely shown to regulate four signalling pathways potentially associated with bipolar disorder: the inhibition of the enzyme glycogen synthase kinase (GSK3) [67,68], the activation of the MAPK signalling pathway [69], the attenuation of inositol signalling [54] and more recently phosphoinositol signalling [70].

A pharmacological approach to understand how VPA and lithium regulate cell signalling therefore requires the understand-
6. MAP Kinase and bipolar disorder

Bipolar disorder has been associated with changes in neurotrophic signalling cascades, neuronal cellular atrophy and regional reductions in brain volume [71,72]. Structural imaging studies of patients with bipolar disorder have demonstrated reduced grey matter volumes in areas of the orbital and medial prefrontal cortex, ventral striatum and hippocampus and enlargement of third ventricles relative to healthy control patients [73,74]. This effect has also been shown in post mortem neuropathological studies with reductions in cortex volume [74], glial cell counts [75] and neuron size in various regions of the prefrontal cortex and amygdala of bipolar disorder patients [73]. Glial cell reductions in these regions are particularly interesting due to the role of these cells in regulating the development and maintenance of synaptic networks. Changes in neurotrophic signalling and atrophy may thus provide the mechanism of bipolar disorder pathology.

Lithium and VPA treatment have been shown to reverse or attenuate brain structural changes found in bipolar disorder [76,77], suggesting this neuroprotective effect to be the key mechanism of bipolar disorder treatment. The effect is thought to occur through the MAPK pathway by increasing the activation (phosphorylation) of the extracellular signal-regulated kinase 2 (ERK2). Increased phosphorylation of ERK2 (pERK2) in response to treatment is seen in cultured neuronal cells, rat hippocampus and frontal cortex and cultured rat thyroid cells [78–80]. As the MAPK pathway has been shown to modulate processes such as neuronal differentiation, neuronal survival and long term neuroplasticity it is likely to be involved in protecting against bipolar disorder-dependent neuronal death and is thus increasingly seen as the potential origin of the disorder [81]. Elucidating how VPA and lithium cause this effect is therefore of great therapeutic interest in understanding bipolar disorder aetiology [80,82].

Employing Dictyostelium has shown that both VPA and lithium also up-regulate the activation of the MAPK pathway [82] by increasing pERK2 levels in this simple biomedical model system (Fig. 2A and B). In the case of VPA, this effect was shown to occur rapidly (within 10 min)—suggesting a biochemical basis for drug action rather than genetic regulation. The mechanism of action was suggested to be independent of upstream regulation, since it was not dependent on receptor phosphorylation (the cAMP receptor 1; cAR1) and to be independent of G protein dissociation (using FRET analysis or genetic deletion of G protein signalling). Furthermore, increased pERK2 levels could not be phenocopied by reducing PIP3 production (using a widely-employed inhibitor to PI3K-family proteins, LY294002). However, a range of experiments suggested that VPA may function through blocking de-phosphorylation of pERK2 (Fig. 2). These experiments showed that pERK2 level up-regulation is phenocopied by a reduced cAMP production (through ablation of adenylate cyclase A); pharmacological inhibition of protein kinase A (PKA) activity and pharmacological inhibition of phosphotyrosine phosphatase activity (by vanadate)—all implicating de-phosphorylation of pERK2 as the mechanism of action for VPA. The interaction of MAPK and cAMP/PKA pathway is complex [83] with multiple points of interaction and cross-regulation. Further analysis of this crosstalk in both Dictyostelium and mammalian systems will be necessary to better define the mechanism of VPA action on this pathway. The results also strongly implicate GSK3/A inhibition in reducing extended pERK2 levels, since both lithium and a specific GSK3/A inhibitor cause increased pERK2 levels at three and four minutes post stimulation [82], as does genetic ablation of GSKA in isogenic cell lines (Fig. 2C). This work also suggests that the lithium-induced pERK2 up-regulation is likely to be caused through direct inhibition of GSK3/A activity, leading to a decrease in PKA/MKP activity. This reasoning is also supported by the observation that ablation of GSK3/A blocks lithium-catalysed extended pathway activation at four minutes post stimulation (Fig. 2A and C). These results suggest that VPA increases activated MAPK levels through inhibition of a cAMP/PKA dependent de-phosphorylation of pERK2 whilst the lithium-dependent effect occurs through GSK3/A-dependent signalling.

One important aspect of VPA pharmacology is the use of compounds related to VPA to distinguish between different targets in cell signalling. These studies were initially based upon the identification of reactive metabolites of VPA. For example β-oxidation of VPA gives rise to the metabolite E-2-propylpent-2-enoic acid whereas the action of the enzyme P450 results in the formation of 3-propylpent-4-enoic acid. These compounds show different inhibitory action towards β-oxidation [84]. Furthermore, the teratogenic effect of VPA is also highly structurally dependent [62], requiring a carboxylic acid head group, a branch point on the second carbon, a hydrogen on the second carbon, and enantiomeric specificity (S-enantiomers show greater teratogenicity than R-enantiomers).

In Dictyostelium we have employed a range of VPA-related compounds to investigate the structural requirements for pERK2 up-regulation, and used this to differentiate this effect from other VPA sensitive pathways, mechanisms of action and therapeutic effects. For example, the amide derivative of VPA (valpromide) showed improved efficacy in seizure control [85] and lacks teratogenicity but shows only intermediate up-regulation of pERK2 levels in Dictyostelium (Fig. 2D). The elevation of pERK2 is also enantiomer specific since S-2-pentyl-4-pentenoic acid is strongly activating compared to its enantiomer R-2-pentyl-4-pentenoic acid that shows little effect (Fig. 2D). Interestingly, these two enantiomers have been shown to improve learning and memory with the more teratogenic S enantiomer exhibiting a stronger potency [86], however this increase was lost due to the detrimental effect on neuronal cell survival caused by teratogenicity. These results would support a role for pERK2 up-regulation in increased memory [86,87], as well as the possibility of increased protection against neuronal damage during bipolar disorder. The Dictyostelium-based studies also identified other, non-teratogenic VPA analogues (e.g. 2-methyl-2-pentenoic acid; Fig. 2D) that show equal efficacy to VPA, thus presenting potentially novel treatments for bipolar disorder. In support of a cAMP/PKA dependent mechanism of bipolar disorder drug action, lithium, carbamazepine [88,89] and VPA [90–92] inhibit cAMP-based signalling in mammalian systems.

Future work regarding VPA-catalysed inhibition of the cAMP/PKA/GSK3 signalling may provide mechanisms for the neuroprotective effects observed in treating bipolar disorder patients [57,80].

7. Inositol and phosphoinositol attenuation and bipolar disorder

Reduced inositol-dependent signalling was the first proposed mechanism for bipolar disorder treatments [54,93], primarily based on a lithium-induced attenuation of inositol recycling through inhibition of inositol monophosphatase (IMPase) and inositol polyphosphate 1-phosphatase (IPPase) [94]. Dictyostelium has since proved an important model for understanding the role of VPA and lithium in regulating inositol signalling.
Fig. 2. MAPK regulation by bipolar disorder treatments in the simple biomedical model Dictyostelium. In both Dictyostelium and mammalian systems, valproic acid (VPA) and lithium (Li⁺) treatment leads to an increase in activated MAPK, illustrated here for the phosphorylation of the ERK2 (extracellular regulated kinase 2 [ERK2]) to form pERK2. (A) Regulation of pERK2 levels is complex, provided by a balance between kinase-dependent phosphorylation (catalysed by MEKK [mitogen-activated protein kinase kinase kinase], and MEK [MAPK kinase kinase]) and by de-phosphorylation (catalysed by MKP [MAP kinase phosphatase] in the PKA [protein kinase A] and GSK3/A [glycogen synthase kinase 3/A] signalling pathways). (B) Treatment of Dictyostelium cells with a single pulse of cyclic AMP (cAMP) gives rise to a transient increase in pERK2 detected by using phosphorylation-specific antibodies. Pre-incubation of Dictyostelium cells with VPA (1 mM, 60 min) increases and elongates the pathway activation by an unknown mechanism. (C) Research in Dictyostelium enables the use of isogenic cell lines containing either ablated or over-expressed genes, providing valuable tools for pharmacological research. For example, we can examine the role of GSKA (homologous to the human GSK3 proteins) in this effect by comparing pERK2 levels in wild-type cells and those lacking GSKA, under control conditions (no added drug) or following Li⁺ (10 mM, 60 min, dark grey) OR VPA (1 mM, 60 min, light grey) treatment. GSKA ablation increases pERK2 levels, suggesting that it functions as a negative regulator of this pathway, as does pharmacological inhibition with Li⁺. The lithium-dependent increase in pERK2 is also significantly reduced in the GSKA null, in agreement with a lithium/GSKA-dependent mechanism of action. In contrast, VPA causes a hypersensitive pERK2 increase in this mutant, suggesting VPA functions through a GSKA-independent mechanism. This approach shows an unambiguous role of GSKA in the transient formation of pERK2. *P < 0.05 compared to control. (D) Novel compounds related to VPA can also be analysed in structure–activity relationship studies (SARs), where for example, the amide derivative of VPA (valpromide), enantiomeric compounds (R- and S-2-pentyl-4-pentynoic acid), and altered branch derivatives (2-ethyl-4-methylpentanoic acid) show altered pathway activation. *P < 0.01, **P < 0.05 compared to control.

Our previous work identified a common effect of VPA and lithium in causing a reduction in InoP₃ signalling in Dictyostelium [95] (Fig. 3). These studies identified prolyl oligopeptidase (PO), in a REMI mutant screen for resistance to the effect of lithium in blocking development [93,95] (Fig. 1). The PO knockout mutant was able to overcome this block and hence form fruiting bodies, by elevating InoP₃ levels. These studies also showed that VPA, lithium and one other bipolar disorder treatment (carbamazepine) induced a common change in mammalian neurons, and that this change could be reversed by the addition of exogenous inositol or by inhibition of PO activity (Fig. 3) [59,93]. This loss of PO activity gave rise to an increase in the breakdown of InoP₄, InoP₅ and InoP₆ to form InoP₃. PO-dependent regulation of cellular InoP₃ levels has since been demonstrated in astrogloma and COS-7 kidney cell lines [96,97]. Thus, PO ablation reverses the common effect of bipolar disorder drugs. This was a novel discovery, since the role of PO was thought to be entirely based upon the cleavage of small peptides containing prolyl residues [98]. A link between PO enzyme activity and bipolar disorder has also been reported in patients that exhibit increased enzyme activity [21]. Furthermore, both Dictyostelium and mammalian systems have been used to identify a range of compounds structurally related to VPA that cause inositol depletion to show that this effect is not correlated with teratogenic activity [59,99].

The mechanism of lithium-dependent inositol phosphate regulation has recently been further characterised in Dictyostelium [100] (Fig. 3). King et al. [100] showed that chemotaxis provides a suitable model for examining the effects of lithium in Dictyostelium, since it causes a strong reduction in cell speed. Ablation of PO activity reduced sensitivity to this lithium effect, consistent with an InoP₃-dependent mechanism of lithium action. Ablation of the enzyme multiple inositol polyphosphate phosphatase (MIPP), responsible for breakdown of InoP₄–6, resulted in reduced InoP₃ levels, whereas MIPP over-expressing cell extracts had an enhanced activity compared to wild type controls. MIPP activity was necessary for PO-inhibition dependent inositol phosphate regulation both in chemotaxis and in the production of InoP₃. These data clearly establish PO as the regulator of MIPP activity. However, surprisingly, over-expression of MIPP gave a lithium hyper-sensitive phenotype. The origin of lithium hyper-sensitivity in cells over-expressing MIPP was found to be due to the elevated expression of a range of genes related to inositol signalling [100]. These included IMPase and IPPase—previously been described as cellular targets of lithium [94] and inositol synthase 1 (INO1)—responsible for di novo synthesis of inositol. The increase in gene expression was also observed following both genetic and pharmacological inhibition of PO activity. However in all cases, this increased expression was dependent upon the presence of MIPP activity and was also induced by over-expression of the kinases responsible for the production of InoP₄–6 from InoP₃. Thus this work identified a gene regulatory mechanism where the activation or over-expression of MIPP leads to elevated expression of a range of inositol regulation genes in Dictyostelium. The results were then successfully translated to human
cells (HEK293) to demonstrate that P0 inhibition also up-regulates several IMPase genes and that this elevation is dependent on MIPP activity. It is of interest that IMPase polymorphisms have been associated with risk of bipolar disorder in family studies [101–103]. A new mechanism of action for bipolar disorder drugs has been recently proposed based upon work in *Dictyostelium* [104,105]. Initially, to characterise a VPA-dependent block in *Dictyostelium* cell movement, we investigated the role of phosphoinositide signalling as a target for VPA action [104]. VPA treatment produced a rapid and strong reduction of phosphoinositide production. Further investigation of this effect in *Dictyostelium* employed cells transformed with a PIP3 binding protein (PHcrac-GFP) enabling the time- and location-dependent monitoring of PIP3 production. VPA produced an acute (10 min) reduction in PIP3 production, also shown by reduced PIP2 and PIP levels using in vivo radio-labelling experiments (Fig. 3A and B, red). These effects were phenocopied by pharmacological inhibition of phosphatidylinositol 3-kinase (PI3K) using the inhibitor LY294002. Identification of the mechanism that cause the inhibitory activity on phosphoinositide signalling is highly complex, since phosphorylation of the phosphatidylinositol head group can occur at three positions on the inositol ring (Fig. 3), creating a variety of products including single phosphorylated moieties (e.g. PI(3)P, PI(4)P, PI(3,4)P2, PI(3,4,5)P3). This data, for the first time, implicated phosphoinositide signalling as a potential target for bipolar disorder treatments. Considerable evidence suggests that elevated phosphoinositide signalling may be an underlying cause of bipolar disorder since a variety of studies have identified this effect in bipolar disorder drug-free patients [106–108] as well as the subsequent down-regulation of phosphoinositide levels following bipolar disorder drug treatment [108,109].

Recent work on the effects of lithium on *Dictyostelium* has now extended the observation that bipolar disorder-treatment attenuates phosphoinositide-mediated signalling [70]. The analysis of the mechanism leading to decreased cell speed following treatment indicated this effect is independently of both CAMP synthesis and F-actin polymerisation. However, the speed reduction was phenocopied by pharmacological or genetic ablation of PI3K activity using either LY294002 or a single *Dictyostelium* cell line lacking all five PI3K genes [36] implicating phosphoinositide signalling as a target for lithium treatment. In agreement with this, the phosphorylation of the protein kinase B (PkbA) homologue, whose membrane translocation is dependent on binding to the PH domain of PIP2, was also decreased following lithium treatment compared to untreated cells. Furthermore, these effects also occurred in conjunction with a decrease in the rate of PIP and PIP2 synthesis, although no changes in steady-state concentration of PIP2 levels were detected. This may be due to a small rapidly turned over pool of PIP2 that is quickly metabolised during chemostaxis providing a lithium sensitive target. Since the mechanism for inositol signalling attenuation by lithium is known to function through the competitive inhibition of IMPase and IPPase [94, King et al. [70] over-expressed IMPase to reverse the effects of lithium in PIP/PIP2 synthesis and PkbA phosphorylation. The results were then successfully reproduced in a human neutrophil cell line (HL60) where the translocation of a PIP2-binding GFP construct to cell membranes (as a readout for PIP3 production) was reduced following lithium treatment. Based on these studies in *Dictyostelium* investigating both VPA and lithium mechanisms of action, we can now propose a new extension of the current of inositol depletion hypothesis, whereby bipolar disorder treatments give rise to attenuated phosphoinositide signalling.

8. Conclusion/summary

To help those diagnosed with bipolar disorder, ongoing research endeavours to identify the cell signalling changes that are targeted by the pharmacological agents, valproic acid and lithium. This approach overcomes the multitude of potential loci implicated in the aetiology of the disorder, but instead focuses on understanding the mechanism(s) leading to symptomatic control. It also enables the identification of new compounds that may be more efficacious or have reduced side effects in bipolar disorder treatment. Research in this area has traditionally used rodents as model organisms,
however the increasing use of other simple model systems such as Dictyostelium provides distinct advantages.

Investigation of cell signalling regulated by VPA and lithium demonstrate that both Dictyostelium and the animal brain respond by elevating pERK2 levels in the MAPK pathway. Analysis of this effect in Dictyostelium has proposed two mechanisms: VPA regulates increased pERK2 levels through inhibition of cAMP/PKA signalling, whereas lithium inhibits GS3/K, with both effects leading to the reduced dephosphorylation of pERK2. The strong biological specificity of this effect in regards to VPA suggests novel compounds may be identified that show improved efficacy for MAPK regulation.

Another cell signalling effect of VPA and lithium in Dictyostelium is the reduction of inositol-dependent signalling. Recent studies have suggested that cellular inositol phosphate levels are controlled by both inositol recycling and the MIPP-catalysed breakdown of higher-order inositol phosphate compounds (InsP4,5) regulated by prolyl oligopeptidase activity. This work has also discovered a transcriptional-based effect, whereby lithium treatment gives rise to altered transcriptional regulation of inositol-signalling related genes. In addition Dictyostelium-based research has discovered a potential key pharmacological target of VPA and lithium in attenuating phosphoinositol signalling, with both drugs causing an acute attenuation of phosphoinositol turnover. In the case of lithium, it is likely that this effect is through inositol signalling attenuation, whereas the mechanism controlled by VPA remains to be determined. These discoveries open up a exciting field of phosphoinositol research, with the promise of new therapies (based around the structure of VPA) showing increased efficacy in phosphoinositide regulation.

This review has summarised current research aimed at unravelling the complex mechanisms of VPA and lithium in regulating cell signalling, and the important role of Dictyostelium as a simple biomedial model for this research. A better understanding of these cell signalling changes may ultimately identify the underlying causes of bipolar disorder and will enable the development of better therapeutic treatments.

Acknowledgements

Wellcome Trust Project Grant 082640 and NC3Rs Grant G0900775 to RSBW, Alzheimer’s research trust PhD scholarship to MHR.

References

[1] Jamison KR. Manic-depressive illness and creativity. Sci Am 1995;272(2):62–7.
[2] Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rossler W. Diagnoses in bipolar disorder. Eur Psychiatry 2003;18(Suppl. 2):S43–50.
[3] Benazzi F. Frequency of bipolar spectrum in 111 private practice depression outpatients. Eur Arch Psychiatry Clin Neurosci 2003;253(4):203–8.
[4] Calabrese JR, Hirschfeld RM, Reed M, Davies MA, Frye MA, Keck PE, et al. Impact of bipolar disorder on a US community sample. J Clin Psychiatry 2003;64(4):425–32.
[5] Evans DL, Clarne DS. Mood disorders and medical illness: a major public health problem. Biol Psychiatry 2003;54(3):177–80.
[6] Ketter TA. Diagnostic features, prevalence, and impact of bipolar disorder. J Clin Psychiatry 2010;71(6):e14.
[7] Tsuchiya K, Agorbo E, Byrne M, Mortensen PB. Higher socioeconomic status of parents may increase risk for bipolar disorder in the offspring. Psychiatr Med 2004;34(5):787–93.
[8] Fujit covering L, Locklear J, Priaux J, Heyes A. A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemiol Ment Health 2009;5:3.
[9] McIntyre RS, Muzina DJ, Kemp DE, Blank D, Woldeyenohannes HO, Lofjoj LF, et al. Bipolar disorders and suicide: research synthesis and clinical translation. Curr Psychiatry Rep 2008;10(1):66–72.
[10] Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olsson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 2007;64(9):1032–9.
[11] Craddock N, Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet 2006;14(6):680–8.
[12] Gould TD, Dow ER, O'Donnell KC, Chen G, Manji HK. Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. CNS Neurol Disord Drug Targets 2007;6(3):193–204.
[13] Flasher-Grinberg S, Kronfeld-Schor N, Einat H. Models of mania: from facets to domains and from animal models to model animals. J Psychopharmacol 2010;24(3):417–8.
[14] Craddock N, Sklar P. Genetics of bipolar disorder: successful start to a long journey. Trends Genet 2009;25(1):99–105.
[15] Baum AE, Akula S, Dixit VM, Cardona I, Corona W, Klemens B, et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008;13(2):197–207.
[16] Craddock N, Jones L, Jones IR, Grozeva D, et al. Strong genetic evidence for a selective influence of GABA(A) receptors on a component of the bipolar disorder phenotype. Mol Psychiatry 2010;15(11):1121.
[17] Fun van der Schot AC, Vonk R, Brants GC, van Haren NE, Koolschijn PC, Nuoee V, et al. Influence of genes and environment on brain volumes in twin pairs concordant and discordant for bipolar disorder. Arch Gen Psychiatry 2009;66(2):142–51.
[18] Moore G, Cortese BM, Glitz DA, Zajac-Benitez C, Quiroz JA, Lhede TV, et al. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 2009;70(5):699–705.
[19] Ensell L, McDonald C. The structural neuroimaging of bipolar disorder. Int Rev Psychiatry 2009;21(4):297–313.
[20] Nakatani N, Hattori E, Ohnishi T, Dean B, Iwawaya Y, Matsumoto J, et al. Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. Mol Hum Mol Genet 2006;15(12):1949–62.
[21] Breen G, Harwood AJ, Gregory K, Sinclair M, Collier D, St CD, et al. Two peptidase activities decrease in treated bipolar disorder not schizophrenic patients. Bipolar Disord 2004;6(2):156–61.
[22] Bazinet RP, Rao JS, Chang L, Rapoport SI, Hjell N. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol Psychiatry 2006;59(5):401–7.
[23] Lee HJ, Rao JS, Chang L, Rapoport SI, Kim HW. Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to ‘switching’ in bipolar disorder? Mol Psychiatry 2010;15(6):602–14.
[24] Kay RR. Differentiation and patterning in Dictyostelium. Curr Opin Genet Dev 1994;4(4):637–41.
[25] Urunushi H. Developmental biology of the social amoeba: history, current knowledge and prospects. Dev Growth Differ 2008;50(Suppl. 1):S277–81.
[26] Kimmel AR, Ferril RA. Breaking symmetries: regulation of Dictyostelium development through chemotaxanttract and morphogen signal–response. Curr Opin Genet Dev 2004;14(5):540–9.
[27] Surel A, Klee YS, Luo T, Robinson DN. Cytokinesis through biochemical–mechanical feedback loops. Semin Cell Dev Biol 2010;19:1373–7.
[28] Butterly NJ, Rozen DE, Wolf JB, Thompson CR. Quantification of social behavior in D. discoideum reveals complex fixed and facultative strategies. Curr Biol 2009;19(16):1373–7.
[29] Eichinger L, Pachebat JA, Glockner G, Rajandream MA, Sugang R, Berriman M, et al. The genome of the social amoeba Dictyostelium discoideum. Nature 2005;435(7038):43–57.
[30] Fey P, Gaudet F, Curk T, Zupan B, Just EM, Basu S, et al. DictyBase—a Dictyostelium bioinformatics resource update. Nucleic Acids Res 2009;37:D515–9 (Database issue).
[31] Kuspa A. Restriction enzyme-mediated integration (REMI) mutagenesis. Methods Mol Biol 2006;346:201–9.
[32] Kuspa A, Loomis WF. REMI-RFLP mapping in the Dictyostelium discoideum. Genetics 1994;138(3):665–74.
[33] Kuspa A, Loomis WF. Tagging developmental genes in Dictyostelium by restriction enzyme-mediated integration of plasmid DNA. Proc Natl Acad Sci USA 1992;89(18):8803–7.
[34] Williams RS. Pharmacogenetics in model systems: defining a common mechanism of action for mood stabilisers. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(10):1229–37.
[35] Faix J, Kreppel L, Shaulsky G, Schleicher M, Kimmel AR. A rapid and efficient method to generate multiple gene disruptions in Dictyostelium discoideum using a single selectable marker and the Cre-loxP system. Nucleic Acids Res 2006;34(12):e143.
[36] Hoeller O, Kay RR. Chemotaxis in the absence of PI3 gradients. Curr Biol 2007;17(9):813–7.
[37] Fischer M, Haase I, Wiesen S, Muller-Taubenberger A. Visualizing cytoskeleton dynamics in mammalian cells using a humanized variant of monomerized red fluorescent protein. FEBS Lett 2006;580(10):2495–502.
[38] Meunier CARRAGAZ, Neunier Y, Eymard P, Aimard M. Pharmacodynamic properties of N-dipropylacetyl. Therapie 1963;18:435–8.
[39] Gysal L, Bowden CL, McElroy SL, Calabrese JR, Petty F, Swann AC, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropharmacology 2003;48(7):1374–82.
[40] Keck Jr PE, McElroy SL. Divalproex in the treatment of bipolar disorder. Psychopharmacol Bull 2003;37(Suppl. 2):97–73.
Einat H, Manji HK. Cellular plasticity cascades: genes-to-behavior pathways

Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases

Gagliardi JP, Krishnan KR. Evidence-based mental health use of anticonvulsants during pregnancy. Psychopharmacol Bull 2003;37(2):59–66.

Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 2006;19(2):272–87.

Abdelaziz MA, Salem H, Kamel M, El Sayed I. Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS One 2010;5(6):e11833.

Brown NA, Farmer PB, Coakley M. Valproic acid teratogenicity: demonstration that the biochemical mechanism differs from that of valproate hepatotoxicity. Biochem Soc Trans 1985;13(5):75–77.

Lisi A, Botto LD, Robert-Gnansia E, Castilla EE, Bakker MK, Bianca S, et al. Surveillance of adverse fetal effects of medications (SAFE-Med): findings from the international clearinghouse of birth defects surveillance and research. Reprod Toxicol 2010;29(4):433–42.

Powell-Jackson PR, Tredger JM, Williams R. Hepatotoxicity to sodium valproate in animal models of bipolar disorder. Biol Psychiatry 2006;59(12):1160–71.

Bazinet RP, Weis MT, Rapoport SI, Rosenberger TA. Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder. Psychopharmacology (Berl) 2006;184(1):122–9.

Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P, et al. Mood stabilizer valproate potentiates inositol 1,4,5-triphosphate concentration by prolyl endopeptidase oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5)-trisphosphate levels. J Neurochem 2008;107(1):514–27.

Montezinho LP, Castro MM, Duarte CB, Penschuck S, Geraldes CF, Mork A. Multiple effects of pentyl-4-yn-VPA enantiomers: from toxicity to short-term memory enhancement. Neuropharmacology 2007;52(3):764–78.

Kalinin A, Abbot F. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-panecitenic acid. Drug Metab Dispos 1993;21(6):1098–106.

Tasso SM, Moon SC, Bruno-Blanch LE, Estiu GL. Characterization of the anticonvulsant profile of valproame derivatives. Biochem Med 2004;14(12):1385–67.

Gotfred K, Owczarek S, Hoffmann K, Klementiev B, Nau H, Berezin V, et al. Multiple effects of pentyl-4-yn-VPA enantiomers: from toxicity to short-term memory enhancement. Neuropharmacology 2007;52(3):764–78.

Dhukav V, Anand KS. Is hippocampal atrophy a future drug target? Med Hypotheses 2007;68(6):1300–6.

Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008;33(9):2080–92.

Boecker K, Adley K, Xu X, Jenkins A, Jin T, Williams RS. The neuroprotective agent, valproic acid, regulates the mitogen-activated protein kinase pathway through modulation of protein kinase A signalling in Dyticystis discoidale. Eur J Cell Biol 2006;85(9–10):1047–57.

Mann L, Heldman E, Shalit A, Johannessen M, Moens U, et al. Reductions in neuronal and glial densities during pregnancy. Psychopharmacol Bull 2003;37(2):59–66.

Strakowski SM, Adler CM, Holland SK, Mills NP, Delbello MP, Elsasser JC. Abnormal FMR1 brain activation in euthymic bipolar disorder patients during performance of Stroop interference task. Am J Psychiatry 2002;159(6):967–70.

Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001;49(9):879–82.

Bukhmut T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 2001;158(1):100–6.

Montezinho LP, Castro MM, Duarte CB, Penschuck S, Geraldes CF, Mork A. Multiple effects of pentyl-4-yn-VPA enantiomers: from toxicity to short-term memory enhancement. Neuropharmacology 2007;52(3):764–78.

Kalinin A, Abbot F. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-panecitenic acid. Drug Metab Dispos 1993;21(6):1098–106.

Tasso SM, Moon SC, Bruno-Blanch LE, Estiu GL. Characterization of the anticonvulsant profile of valproame derivatives. Biochem Med 2004;14(12):1385–67.

Gotfred K, Owczarek S, Hoffmann K, Klementiev B, Nau H, Berezin V, et al. Multiple effects of pentyl-4-yn-VPA enantiomers: from toxicity to short-term memory enhancement. Neuropharmacology 2007;52(3):764–78.

Kalinin A, Abbot F. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-panecitenic acid. Drug Metab Dispos 1993;21(6):1098–106.

Tasso SM, Moon SC, Bruno-Blanch LE, Estiu GL. Characterization of the anticonvulsant profile of valproame derivatives. Biochem Med 2004;14(12):1385–67.

Gotfred K, Owczarek S, Hoffmann K, Klementiev B, Nau H, Berezin V, et al. Multiple effects of pentyl-4-yn-VPA enantiomers: from toxicity to short-term memory enhancement. Neuropharmacology 2007;52(3):764–78.

Dhukav V, Anand KS. Is hippocampal atrophy a future drug target? Med Hypotheses 2007;68(6):1300–6.

Mann L, Heldman E, Shalit A, Johannessen M, Moens U, et al. Reductions in neuronal and glial densities during pregnancy. Psychopharmacol Bull 2003;37(2):59–66.

Strakowski SM, Adler CM, Holland SK, Mills NP, Delbello MP, Elsasser JC. Abnormal FMR1 brain activation in euthymic bipolar disorder patients during performance of Stroop interference task. Am J Psychiatry 2002;159(6):967–70.

Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001;49(9):879–82.

Bukhmut T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 2001;158(1):100–6.

Montezinho LP, Castro MM, Duarte CB, Penschuck S, Geraldes CF, Mork A. The interaction between dopamine D2-like and beta-adrenergic receptors in the prefrontal cortex is altered by mood-stabilizing agents. J Neurochem 2006;99(6):1336–48.

Montezinho LP, Mork A, Duarte CB, Penschuck S, Geraldes CF, Castro MM. Effects of mood stabilizers on the inhibition of adenylate cyclase via dopamine D(2)-like receptors. Bipolar Disord 2007;9(3):290–7.

Gallagher HC, Bacon CL, Oudemur OA, Gallagher FF, Fitzpatrick T, Regan CM. Valproate activates phosphodiesterase-mediated AMP degradation: relevance to C6 glioma G1 phase progression. Neurotoxicol Teratol 2004;26(1):71–83.

Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism for severe mood disorders: implications for the development of novel therapeutics. Mol Neurobiol 2008;33(9):292–3.

Galaborski JP, Krishnan KR. Evidence-based mental health use of anticonvulsants during pregnancy. Psychopharmacol Bull 2003;37(2):59–66.

Doble BW, Woodgett JR, Chambon P. Triggers of the track for a multi-tasking kinase. J Cell Sci 2003;116(7):1175–86.

Joep RS, Roht MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006;7(11):1421–34.

Eitan H, Manji HK, Charney DS. Impairments of neuronal plasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001;35(2):5–49.

Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive functional features of mood disorders. Curr Opin Neurobiol 2001;11(2):240–9.

Strakowski SM, Adler CM, Holland SK, Mills NP, Delbello MP, Elsasser JC. Abnormal FMR1 brain activation in euthymic bipolar disorder patients during performance of Stroop interference task. Am J Psychiatry 2002;159(6):967–70.

Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001;49(9):879–82.

Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999;72(2):129–36.

Broocks TM, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 2001;158(1):100–6.
[98] Williams RSB. Prolyl oligopeptidase and bipolar disorder. Clinical Neuroscience Research 2004;4(3–4):233–42.

[99] Shimshoni JA, Dalton EC, Jenkins A, Eyal S, Ewan K, Williams RS, et al. The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. Mol Pharmacol 2007;71(3):884–92.

[100] King J, Keim M, Teo R, Weening KE, Kapur M, McQuillan K, et al. Genetic control of lithium sensitivity and regulation of inositol biosynthetic genes. PLoS One 2010;5(6):e11151.

[101] Sjoholt G, Ebstein RP, Lie RT, Berle JO, Mallet J, Deleuze JF, et al. Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder. Mol Psychiatry 2004;9(6):621–9.

[102] Sjoholt G, Gulbrandsen AK, Lovlie R, Berle JO, Molven A, Steen VM. A human myo-inositol monophosphatase gene (IMPA2) localized in a putative susceptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients. Mol Psychiatry 2000;5(2):172–80.

[103] Ohnishi T, Yamada K, Ohba H, Iwayama Y, Toyota T, Hattori E, et al. A promoter haplotype of the inositol monophosphatase 2 gene (IMPA2) at 18p11.2 confers a possible risk for bipolar disorder by enhancing transcription. Neuropsychopharmacology 2007 Aug;32(8):1727–37.

[104] Xu X, Muller-Taubenberger A, Adley KE, Pawolleck N, Lee VW, Wiedemann C, et al. Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot Cell 2007;6(6):899–906.

[105] Pawolleck N, Williams RS. Quantifying in vivo phosphoinositide turnover in chemotactically competent Dictyostelium cells. Methods Mol Biol 2009;571:283–90.

[106] Brown AS, Mallinger AG, Renbaum LC. Elevated platelet membrane phosphatidylinositol-4,5-bisphosphate in bipolar mania. Am J Psychiatry 1993;150(8):1252–4.

[107] Soares JC, Dippold CS, Mallinger AG. Platelet membrane phosphatidylinositol-4,5-bisphosphate alterations in bipolar disorder–evidence from a single case study. Psychiatry Res 1997;69(2–3):197–202.

[108] Soares JC, Mallinger AG, Dippold CS, Forster WK, Frank E, Kupfer DJ. Effects of lithium on platelet membrane phosphoinositides in bipolar disorder patients: a pilot study. Psychopharmacology (Berl) 2000;145(1):12–6.

[109] Pandey GN, Ren X, Dwivedi Y, Pavuluri MN. Decreased protein kinase C (PKC) in platelets of pediatric bipolar patients: effect of treatment with mood stabilizing drugs. J Psychiatr Res 2008;42(2):106–16.